Volition, a multi-national company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers.

**Early Diagnosis is Key**

As cancer screening programs become more and more widespread, our products can help to diagnose a range of cancers quickly, simply, accurately and cost effectively. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life.

**Financial Snapshot**

Ticker: NYSE AMERICAN: VNRX  
Sector: Healthcare: Diagnostics & Research  
Market Cap: $78.5m*  
52 week range: $2.45-$5.86*  
Cash-on-hand: $16.5m**  
*As of August 31st, 2017  
**As of June 31st, 2017

**Rethinking the Approach to Cancer**

“Current cancer diagnosis frequently involves expensive, unpleasant and, often, invasive testing. Using our Nu.Q™ technology we aim to make cancer diagnosis as accessible as cholesterol or pregnancy testing”

Dr. Jake Micallef, Chief Scientific Officer

Nu.Q™ represents a powerful step change in rethinking the approach to cancer. It is a simple solution to the challenging problem of early cancer diagnosis. **A simple test, with a small amount of blood.**

Nu.Q’s™ unique technology looks for very early ‘nucleosomic’ markers of cancer. Nu.Q™ uses an array of simple, cost-effective, and accurate blood tests. These tests may identify early stage cells before the cancer spreads; providing medical professionals increased diagnostic power. Nu.Q™ can potentially reduce the strain on over-burdened healthcare systems.
Colorectal Cancer
Volition’s initial Nu.Q™ products are focusing on colorectal cancer. Colorectal cancer is responsible for over 200,000 deaths in Europe each year, almost 50,000 deaths in the USA and nearly 700,000 deaths worldwide.

- Interim results of a panel of 4 Nu.Q™ assays detected 81% of colorectal cancers at 78% specificity (vs. Healthy) in a cohort of 4,800 symptomatic patients.
- A panel of 4 normalised Nu.Q™ assays detected 67% of high risk adenomas at 80% specificity in a cohort of 530 symptomatic patients.
- A panel of 4 Nu.Q™ assays demonstrated CRC detection accuracy of 74% sensitivity at 90% specificity and detected all stages of the cancer, including 75% of early stage I cancers.
- This study of 58 asymptomatic patients also showed that by using an age adjusted scoring system the accuracy of CRC detection increased to 91% of cancers at 90% specificity.

Pancreatic Cancer
There is a clear medical need for a reliable, simple, and accurate diagnostic test for pancreatic cancer. Currently, emergency presentation is the most common route to diagnosis, and only 21% of patients survive for more than a year.

- A panel of 4 Nu.Q™ assays plus CA19-9 in a pilot study of 59 patients detected 92% of pancreatic cancers at 90% specificity.
- Interim results of a panel of 2 Nu.Q™ assays plus CEA detected 95% of pancreatic cancers at 84% specificity.

Lung Cancer
Lung cancer is the most common cancer worldwide. Only 10% of lung cancer patients will survive for five years or more. Current screening methods for lung cancer are widely regarded as too inaccurate and expensive for widespread use.

- A panel of 4 Nu.Q™ assays in a pilot study of 73 patients detected 93% of lung cancers at 91% specificity.

Ongoing Clinical Trials

<table>
<thead>
<tr>
<th>Institution</th>
<th>Condition</th>
<th>Sample Collection</th>
<th>Cohort</th>
</tr>
</thead>
<tbody>
<tr>
<td>Early Detection Research Network of the U.S. National Cancer Institute</td>
<td>Colorectal cancer</td>
<td>9000 Prospective</td>
<td>13,500 screening population</td>
</tr>
<tr>
<td>Hvidovre Hospital, University of Copenhagen</td>
<td>Colorectal cancer</td>
<td>Retrospective</td>
<td>4,800 symptomatic</td>
</tr>
<tr>
<td>Hvidovre Hospital, University of Copenhagen</td>
<td>Colorectal cancer</td>
<td>Prospective</td>
<td>14,000 screening population</td>
</tr>
<tr>
<td>Hvidovre Hospital, University of Copenhagen</td>
<td>Colorectal cancer and other cancers</td>
<td>Prospective, longitudinal</td>
<td>30,000 screening population to provide 3 samples (90,000 samples total)</td>
</tr>
<tr>
<td>University of Bonn</td>
<td>27 most prevalent cancers</td>
<td>Prospective</td>
<td>4,700</td>
</tr>
<tr>
<td>German Cancer Research Center (DKFZ)</td>
<td>Pancreatic</td>
<td>Retrospective</td>
<td>750</td>
</tr>
</tbody>
</table>

U.S Colorectal Cancer Screening Trial
Volition is part of a large multi-center clinical study with the renowned U.S. National Cancer Institute’s (NCI) Early Detection Research Network (EDRN). The study is aimed to validate Nu.Q™ Colorectal Cancer Screening Test. Volition America will only contribute up to $3 million towards the cost, which is excellent value for money.

Our Expert Team
Volition was established in 2010 when our team saw a chance to bring together the long-established ELISA diagnostic technology with cutting-edge nucleosome detection and analysis techniques. We have grown over the years and are now a collective force of distinct individuals with a single aim – to save lives by revolutionizing the way cancer is diagnosed.

Cameron Reynolds MBA
President & Chief Executive Officer

Jake Micallef PhD MBA
Chief Scientific Officer

Jason Terrell MD
Chief Medical Officer & Chief Executive Officer of Volition America, Inc.

Jasmine Kway PhD
Vice President of Asia

Louise Day
Chief Marketing & Communications Officer

Gaetan Michel PhD
Chief Executive Officer, Belgian Volition SPRL

David Vanston FCCA
Chief Financial Officer

Rod Rootsaert LLB
Corporate Secretary

Contact: investorrelations@volitionrx.com